TY - JOUR
T1 - Cerebrospinal fluid in the diagnosis of multiple sclerosis
T2 - A consensus report
AU - Andersson, M.
AU - Alvarez-Cermeñio, J.
AU - Bernardi, G.
AU - Cogato, I.
AU - Fredman, P.
AU - Frederiksen, J.
AU - Fredrikson, S.
AU - Gallo, P.
AU - Grimaldi, L. M.
AU - Grønning, M.
AU - Keir, G.
AU - Lamers, K.
AU - Link, H.
AU - Magalhães, A.
AU - Massaro, A. R.
AU - Öhman, S.
AU - Reiber, H.
AU - Rönnbäck, L.
AU - Schluep, M.
AU - Schuller, E.
AU - Sindic, C. J M
AU - Thompson, E. J.
AU - Trojano, M.
AU - Wurster, U.
PY - 1994
Y1 - 1994
N2 - The Committee of the European Concerted Action for Multiple Sclerosis (Charcot Foundation) organised five workshops to discuss CSF analytical standards in the diagnosis of multiple sclerosis. This consensus report from 12 European countries summarises the results of those workshops. It is hoped that neurologists will confer with their colleagues in clinical chemistry to arrange the best possible local practice. The most sensitive method for the detection of oligoclonal immunoglobulin bands is isoelectric focusing. The same amounts of IgG in parallel CSF and serum samples are used and oligoclonal bands are revealed with IgG specific antibody staining. All laboratories performing isoelectric focusing should check their technique at least annually using "blind" standards for the five different CSF and serum patterns. Quantitative measurements of IgG production in the CNS are less sensitive than isoelectric focusing. The preferred method for detection of blood-CSF barrier dysfunction is the albumin quotient. The CSF albumin or total protein concentrations are less satisfactory. These results must be interpreted with reference to the age of the patient and the local method of determination. Cells should be counted. The normal value is no more than 4 cells/μl. Among evolving optional tests, measurement of the combined local synthesis of antibodies against measles, rubella, and/or varicella zoster could represent a significant advance if it offers higher specificity (not sensitivity) for identifying chronic rather than acute inflammation. Other tests that may have useful correlations with clinical indices include those for oligoclonal free light chains, IgM, IgA, or myelin basic protein concentrations.
AB - The Committee of the European Concerted Action for Multiple Sclerosis (Charcot Foundation) organised five workshops to discuss CSF analytical standards in the diagnosis of multiple sclerosis. This consensus report from 12 European countries summarises the results of those workshops. It is hoped that neurologists will confer with their colleagues in clinical chemistry to arrange the best possible local practice. The most sensitive method for the detection of oligoclonal immunoglobulin bands is isoelectric focusing. The same amounts of IgG in parallel CSF and serum samples are used and oligoclonal bands are revealed with IgG specific antibody staining. All laboratories performing isoelectric focusing should check their technique at least annually using "blind" standards for the five different CSF and serum patterns. Quantitative measurements of IgG production in the CNS are less sensitive than isoelectric focusing. The preferred method for detection of blood-CSF barrier dysfunction is the albumin quotient. The CSF albumin or total protein concentrations are less satisfactory. These results must be interpreted with reference to the age of the patient and the local method of determination. Cells should be counted. The normal value is no more than 4 cells/μl. Among evolving optional tests, measurement of the combined local synthesis of antibodies against measles, rubella, and/or varicella zoster could represent a significant advance if it offers higher specificity (not sensitivity) for identifying chronic rather than acute inflammation. Other tests that may have useful correlations with clinical indices include those for oligoclonal free light chains, IgM, IgA, or myelin basic protein concentrations.
UR - http://www.scopus.com/inward/record.url?scp=0028037604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028037604&partnerID=8YFLogxK
U2 - 10.1136/jnnp.57.8.897
DO - 10.1136/jnnp.57.8.897
M3 - Article
C2 - 8057110
AN - SCOPUS:0028037604
VL - 57
SP - 897
EP - 902
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
SN - 0022-3050
IS - 8
ER -